Common microdosing levels include: 0.25 mg: Often used as an ultra-low starting point for highly sensitive individuals
During the first month of GLP-1 use, it is estimated that individuals lose 60/40% fat and muscle, which is problematic.[6] Not only are users potentially getting fatter by proportion, but they are also losing skeletal muscle which is essential to blood sugar regulation and overall longevity
So is magnesium, vitamin D3, and the other micronutrients that keep your energy systems running
Similarly, SM102, a novel long-acting GLP-1RA structurally related to semaglutide, demonstrated robust efficacy in the db/db mouse model
It supports blood sugar control while keeping the effect tied to elevated glucose, which is one reason these medicines are now used across both diabetes and obesity care